Ladenburg, Germany, 27 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the treatment of multiple myeloma to its lead candidate HDP-101. Heidelberg Pharma is investigating the […]
First efficacy data from the clinical trial with HDP-101 in multiple myeloma Expansion of the ADC technology platform to include further payloads New Management Board team Successful financing activities; sales revenue and other income above plan Conference call to be held on 25 March 2024 at 03:00 pm CET/ 10:00 am EDT Ladenburg, Germany, 25 […]
Ladenburg, Germany, 19 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced the formal closing of the royalty purchase agreement with HealthCare Royalty (HCRx) for Zircaix®, signed earlier this month. Under the terms of the agreement, Heidelberg Pharma has received an upfront, non-refundable cash payment of […]
Data from HDP-101 dose escalation shows first objective responses and partial remissions in Cohort 5 Amended protocol includes expanded Cohort 6 with dose optimization, including three parallel arms at different dosing regimens Revolutionizing treatment options for multiple myeloma patients with its proprietary novel payload with a unique mode of action Ladenburg, Germany, 18 March 2024 […]
Ladenburg, Germany, 6 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs) will be presenting first efficacy data on its Phase I clinical trial with ATAC candidate HDP-101 as well as preclinical data on other drug candidates from its proprietary ADC technology platform at the American […]
